Combined Oral Contraceptive
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Combined oral contraceptives (COCs) contain synthetic estrogen (usually ethinyl estradiol 20–35 mcg) and a progestin component. They are primarily used for contraception but are also prescribed for menstrual regulation, dysmenorrhea, endometriosis, acne, and polycystic ovary syndrome (PCOS). They are among the most widely used medications worldwide with an extensive safety record when appropriately prescribed.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Combined oral contraceptives (COCs) contain synthetic estrogen (usually ethinyl estradiol 20–35 mcg) and a progestin component. NutriStack rates the supporting evidence as strong. Common adult dosing is Ethinyl estradiol 20–35 mcg + progestin (varies by product); taken once daily for 21–24 active days followed by 4–7 placebo days (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete vitamin b6, vitamin b12, folate. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: highly effective contraception (>99% with perfect use), menstrual cycle regulation, reduced dysmenorrhea and menstrual blood loss. 10 sources indexed (2020–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
The progestin component suppresses the LH surge, preventing ovulation, while both the estrogen and progestin thicken cervical mucus (impeding sperm penetration), thin the endometrial lining (reducing implantation potential), and alter tubal motility. The estrogen component also suppresses FSH, preventing follicular development, and stabilizes the endometrium to prevent breakthrough bleeding.
Dosing & protocol.
Can be taken with or without food. Take at the same time each day for optimal efficacy. Vomiting or diarrhea within 2 hours of taking may reduce effectiveness.
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Vitamin B6
ModerateEstrogen-containing contraceptives can increase vitamin B6 turnover and lower circulating PLP in susceptible users.
Vitamin B12
MildLong-term oral contraceptive use is associated with lower measured B12 status, likely from altered binding proteins and absorption dynamics.
Folate
ModerateEstrogen-progestin contraceptives can lower folate status through altered metabolism and increased requirement in some users.
Magnesium
MildOral contraceptives are associated with lower magnesium status in some users, likely through altered renal handling and demand.
Zinc
MildEstrogen-containing contraceptives can modestly lower zinc status, likely through altered hepatic protein synthesis and increased losses.
Vitamin C
MildSome users show lower plasma vitamin C during chronic oral contraceptive use, likely from increased oxidative turnover.
Selenium
MildEstrogen-containing contraceptives can modestly alter selenium handling and lower functional selenium status in some users.
Full Combined Oral Contraceptive depletion and interaction guide →
Full safety detail.
Side effects
- Nausea (usually transient, improves after 1–3 cycles)
- Breast tenderness
- Headache
- Breakthrough bleeding or spotting
- Mood changes
- Decreased libido in some women
- Venous thromboembolism (3–4x baseline risk, still low absolute risk)
- Weight changes (minimal with modern formulations)
Contraindications
- Smoking in women over 35 years old (significantly increased cardiovascular risk)
- History of or current venous thromboembolism (DVT/PE)10,7
- History of stroke or ischemic heart disease
- Migraine with aura at any age
- Known thrombophilia (Factor V Leiden, etc.)8
- Breast cancer (current or within 5 years)8,2
- Severe hepatic disease or liver tumors2
- Uncontrolled hypertension (≥160/100 mmHg)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelinesPMIDPiacenti I, Tius V, Viscardi MF et al. · Acta obstetricia et gynecologica Scandinavica · 2025
Piacenti I, Tius V, Viscardi MF et al.. Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelines. Acta obstetricia et gynecologica Scandinavica. 2025
- 2Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysisPMIDWatling CZ, Sweetland S, Wojt A et al. · The Lancet. Oncology · 2025
Watling CZ, Sweetland S, Wojt A et al.. Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis. The Lancet. Oncology. 2025
- 3The Effect of Hormonal Contraceptive Use on Skeletal Muscle Hypertrophy, Power and Strength Adaptations to Resistance Exercise Training: A Systematic Review and Multilevel Meta-analysisPMIDNolan D, McNulty KL, Manninen M et al. · Sports medicine (Auckland, N.Z.) · 2024
Nolan D, McNulty KL, Manninen M et al.. The Effect of Hormonal Contraceptive Use on Skeletal Muscle Hypertrophy, Power and Strength Adaptations to Resistance Exercise Training: A Systematic Review and Multilevel Meta-analysis. Sports medicine (Auckland, N.Z.). 2024
- 4Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort StudiesPMIDBrabaharan S, Veettil SK, Kaiser JE et al. · JAMA network open · 2022
Brabaharan S, Veettil SK, Kaiser JE et al.. Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies. JAMA network open. 2022
- 5A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral ContraceptivePMIDLeelakanok N, Methaneethorn J · Clinical drug investigation · 2020
Leelakanok N, Methaneethorn J. A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Clinical drug investigation. 2020
Reference material
5- 6Curtis KM et al. U.S. medical eligibility criteria for contraceptive use, 2016 (US MEC). MMWR Recomm Rep. 2016;65(3):1-103.Source linkedPMID
- 7de Bastos M et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813.Source linkedPMID
- 8Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data. Lancet. 1996;347(9017):1713-1727.Source linkedPMID
- 9Melin J, Forslund M, Alesi S et al.. Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. The Journal of clinical endocrinology and metabolism. 2024Source linkedPMID
- 10Morimont L, Haguet H, Dogné JM et al.. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in endocrinology. 2021Source linkedPMID
Common questions.
Quick answers about Combined Oral Contraceptive, drawn from the data on this page.
What is Combined Oral Contraceptive?
Combined oral contraceptives (COCs) contain synthetic estrogen (usually ethinyl estradiol 20–35 mcg) and a progestin component. They are primarily used for contraception but are also prescribed for menstrual regulation, dysmenorrhea, endometriosis, acne, and polycystic ovary syndrome (PCOS). They are among the most widely used medications worldwide with an extensive safety record when appropriately prescribed.
What is Combined Oral Contraceptive used for?
Commonly cited benefits of Combined Oral Contraceptive include: Highly effective contraception (>99% with perfect use); Menstrual cycle regulation; Reduced dysmenorrhea and menstrual blood loss; Improvement in acne and hirsutism; Reduced risk of ovarian and endometrial cancer with long-term use. NutriStack rates the overall evidence as strong.
What is a typical dose of Combined Oral Contraceptive?
A typical adult dose of Combined Oral Contraceptive is Ethinyl estradiol 20–35 mcg + progestin (varies by product); taken once daily for 21–24 active days followed by 4–7 placebo days (as prescribed by your physician). The commonly recommended form is Oral tablet; taken daily at the same time each day. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Combined Oral Contraceptive?
Reported side effects include nausea (usually transient, improves after 1–3 cycles), breast tenderness, headache, breakthrough bleeding or spotting, mood changes, decreased libido in some women. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Combined Oral Contraceptive?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Combined Oral Contraceptive in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.